Health Affairs August 25, 2021
Esther Krofah, Steven K. Galson, Robert M. Califf, Gregory Simon

Editor’s Note

This post is part of the Health Affairs Blog short series, “Envisioning A Transformed Clinical Trials Enterprise For 2030.” The series explores ideas for advancing a clinical trials enterprise that is more efficient, effective, person-centered, inclusive, and integrated into the health delivery system of 2030 than is currently the case. The series is being published in conjunction with a four-part public workshop, Envisioning a Transformed Clinical Trials Enterprise in 2030, convened under the auspices of the National Academies Forum on Drug Discovery, Development, and Translation. Posts in this series are published by Health Affairs Blog with the support of the National Academies, but they represent the opinions of the authors and do not necessarily represent the views of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Medical Devices, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article